Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · IEX Real-Time Price · USD
1.79
0.04 (2.29%)
At close: May 20, 2022 4:00 PM
1.89
0.10 (5.59%)
After-hours:May 20, 2022 7:48 PM EDT
Market Cap133.64M
Revenue (ttm)33.44M
Net Income (ttm)-14.61M
Shares Out74.66M
EPS (ttm)-0.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume585,370
Open1.81
Previous Close1.75
Day's Range1.78 - 1.83
52-Week Range1.72 - 10.30
Beta1.73
AnalystsBuy
Price Target10.46 (+484.4%)
Earnings DateMay 10, 2022

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to ma...

IndustryHealth Care Equipment & Supplies
IPO DateAug 12, 2004
CEODavid Fischel
Employees130
Stock ExchangeNYSEAMERICAN
Ticker SymbolSTXS
Full Company Profile

Financial Performance

In 2021, Stereotaxis's revenue was $35.02 million, an increase of 31.51% compared to the previous year's $26.63 million. Losses were -$10.72 million, 61.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for STXS stock is "Buy." The 12-month stock price forecast is 10.46, which is an increase of 484.36% from the latest price.

Price Target
$10.46
(484.36% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Stereotaxis Reports 2022 First Quarter Financial Results

ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results ...

1 week ago - GlobeNewsWire

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology Denmark's only robotic...

2 weeks ago - GlobeNewsWire

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Hear...

Stereotaxis robotic technology now in use in 25 countries Stereotaxis robotic technology now in use in 25 countries

1 month ago - GlobeNewsWire

Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis

Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use spa...

2 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Stereotaxis Reports 2021 Full Year Financial Results

ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

2 months ago - GlobeNewsWire

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fisch...

3 months ago - GlobeNewsWire

Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will rel...

3 months ago - GlobeNewsWire

Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disord...

ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China C...

3 months ago - GlobeNewsWire

HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders

ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has estab...

3 months ago - GlobeNewsWire

Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in N...

ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis  (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Fr...

5 months ago - GlobeNewsWire

Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an ...

6 months ago - GlobeNewsWire

BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment

ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare h...

6 months ago - GlobeNewsWire

Stereotaxis Reports 2021 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...

6 months ago - GlobeNewsWire

Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Me...

ST. LOUIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the F...

6 months ago - GlobeNewsWire

Earnings Preview: Stereotaxis Inc. (STXS) Q3 Earnings Expected to Decline

Stereotaxis Inc. (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Stereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021

ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...

6 months ago - GlobeNewsWire

First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology

ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its ...

7 months ago - GlobeNewsWire

Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance te...

8 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 33.33% and 10.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Stereotaxis Reports 2021 Second Quarter Financial Results

ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...

9 months ago - GlobeNewsWire

Stereotaxis Inc. (STXS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Stereotaxis Inc. (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of M...

9 months ago - GlobeNewsWire

Here's Why "Trend" Investors Would Love Betting on Stereotaxis Inc. (STXS)

If you are looking for stocks that are well positioned to maintain their recent uptrend, Stereotaxis Inc. (STXS) could be a great choice. It is one of the several stocks that passed through our "Recent ...

10 months ago - Zacks Investment Research